Core Insights - A new study published by Tilray Medical focuses on the bioavailability of different cannabinoid formulations, specifically comparing Tilray's THC:CBD extract and nabiximols [1][4] Group 1: Study Overview - The study assessed pharmacokinetic parameters and relative bioavailability of two formulations: Tilray THC:CBD extract (10 mg/mL each of THC and CBD) and nabiximols (total dose of 10.8 mg THC and 10 mg CBD) [2] - Conducted with twelve healthy volunteers, the study revealed that the Cmax for THC and CBD was significantly higher for the Tilray extract compared to nabiximols [3] Group 2: Key Findings - The study found that THC and CBD were undetectable 24 hours post-dose, and 11-OH-THC was markedly reduced from its peak [3] - No serious adverse events were reported during the study, indicating a favorable safety profile for the Tilray formulation [3] Group 3: Implications and Future Directions - The findings suggest that the oral administration of Tilray's THC:CBD extract may achieve higher cannabinoid concentrations more quickly than nabiximols, which could have significant implications for therapeutic use [4] - Tilray's Medical Director emphasized the importance of understanding cannabinoid pharmacokinetics to enhance therapeutic outcomes [5]